Masimo (MASI)
(Delayed Data from NSDQ)
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth D Momentum B VGM
Zacks News
Masimo (MASI) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 8.97% and 4.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo (MASI) Introduces Automation and Connectivity Solution
by Zacks Equity Research
Masimo's (MASI) UniView: 60 leverages the Masimo Hospital Automation platform to boost clinical workflows.
4 Telehealth Stocks to Gain on Virtual Response to Coronavirus
by Sreoshi Bera
Advancement in technology has helped cater to the growing medical demand during the coronavirus pandemic. Here are four telehealth stocks set to boom.
Masimo's New Solution to Reduce Opioid Withdrawal Symptoms
by Zacks Equity Research
Masimo's (MASI) new solution can help reduce symptoms associated with opioid withdrawal, thereby helping OUD patients with their treatment.
Masimo's (MASI) New Offering to Improve Patient Outcomes
by Zacks Equity Research
Masimo's (MASI) Centroid gets FDA clearance and can help clinicians monitor patient position, thereby improving patient outcomes.
Remote Patient Monitoring Gains Prominence: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on three stocks that are committed toward enhancing and offering RPM to fight against coronavirus.
Masimo (MASI) Boosts Product Portfolio with New Solution
by Zacks Equity Research
Masimo (MASI) unveils Masimo Sleep to help consumers better understand their quality of sleep.
Masimo Launches Masimo SafetyNet-Open to Fight Coronavirus
by Zacks Equity Research
Masimo's (MASI) newly-launched SafetyNet-Open has been developed to ensure health and safety during the coronavirus outbreak.
3 Digital HealthCare Stocks in the Spotlight Amid Coronavirus
by Sriparna Ghosal
In the face of the pandemic, the digital health management space continues to thrive on a number of positive developments.
Masimo (MASI) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Masimo (MASI) closed the most recent trading day at $220.24, moving +0.75% from the previous trading session.
Why Is Masimo (MASI) Up 5.3% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain Masimo Stock (MASI) For Now
by Zacks Equity Research
Investor confidence remains high in Masimo (MASI) stock, thanks to solid prospects.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Masimo (MASI) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Masimo (MASI) sees solid growth in key Product segment in Q1.
Masimo Collaborates With Samsung to Help Fight Coronavirus
by Zacks Equity Research
Masimo (MASI) and Samsung Electronics America collaborate to bring Masimo SafetyNet Patient App on the latter's select smartphones for faster distribution of Masimo SafetyNet to COVID-19 patients.
DexCom (DXCM) Jumps: Stock Rises 5.6%
by Zacks Equity Research
DexCom (DXCM) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Zoom Video, Capri, Teladoc Health, Allscripts Healthcare Solutions and Masimo highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Zoom Video, Capri, Teladoc Health, Allscripts Healthcare Solutions and Masimo highlighted as Zacks Bull and Bear of the Day
Trump Plans Steady Economic Reboot: 5 Coronavirus-Proof Bets
by Aniruddha Ganguly
Here we discuss five stocks poised to gain maximum benefits from the staggered reopening of U.S. economy, per the latest guidelines.
Coronavirus Puts Digital Health in Focus: 3 Stocks to Watch
by Trina Mukherjee
Let's keep a watch on three stocks that are focusing on digital health to fight against coronavirus.
Here's Why Momentum Investors Will Love Masimo (MASI)
by Zacks Equity Research
Does Masimo (MASI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
ResMed (RMD) Grows on Stellar Mask Sales, SaaS Capabilities
by Zacks Equity Research
Within SaaS, ResMed (RMD) shows strong momentum in the Brightree service portfolio.
Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo
by Zacks Equity Research
Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo
Here's Why You Should Invest in Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to gain traction from its robustly performing CVI and CSI businesses.